Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) –
Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
Other publications by Fumi Takatsuki
- 2024.09.26
- Legal Affairs for Chinese Life Sciences and Healthcare No. 22: Shanghai Cosmetics Industry Advertising Compliance Guidelines
- 2024.01.24
- Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
- 2023.11.28
- Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
- 2023.10.27
- Publication of the Draft Revisions to the Product Quality Law of China
- 2023.08.28
- Obligation to Establish a Quality and Safety Management System in China
- 2023.07.25
- Legal Affairs for Chinese Life Sciences and Healthcare No.19: Handling and Transborder Transfer of Human Genetic Resources and Information in Chinese Domestic Clinical Trials and Scientific Research
- 2023.05.24
- Legal Affairs for Chinese Life Sciences and Healthcare No.18: Enactment of Regulations on Toothpaste in China
- 2023.03.28
- Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
- 2023.02.28
- Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
- 2023.02.27
- China’s Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
- 2023.01.20
- Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
- 2022.11.29
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 14) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
- 2022.10.25
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 13) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
- 2022.07.14
- Theory and Practice of Chinese Commercial Dispute Resolution（27）Consumer Contracts and Arbitration Clauses
- 2022.07.04
- China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
- 2022.05.26
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
- 2022.03.24
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
- 2022.03.14
- A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
- 2022.02.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
- 2022.01.25
- Employment and Immigration Law Guide 2022 Jurisdiction:Japan
- 2022.01.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
- 2021.10.28
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) –
Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
- 2021.09.30
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
- 2021.08.30
- Legal Affairs for Chinese Life Sciences and Healthcare
- 2019.10.15
- Points to Consider Regarding Advertising Expressions when Doing Business in China
- 2019.05.10
- Case Study on Court Judgement in China Regarding Recognition and Enforcement of Foreign or External Arbitral Award
- 2018.12.10
- Acts against Unjustifiable Advertisement and Misleading Representations in China
- 2018.04.24
- Case Study on Court Judgment in China Regarding Recognition and Enforcement of Foreign Arbitral Award (14)
- 2017.12.27
- 100 Selected Cases in China, Series 250
- 2017.07.10
- Office 40s: Business Legal Affairs: Theory and Practice regarding Civil and Commercial Laws in China [113]
- 2016.11.10
- Recent Developments in Chinese Business Law, No. 50: Toward an Improved Cooling-off System
- 2016.08.15
- 100 Selected Cases in China, Series 234: A Case where the Court Recognized and Enforced an Award in a Foreign Arbitration between Chinese Domestic Companies Concerning Domestic Trade in China
- 2016.03.10
- Latest Updates on Chinese Business Legal Affairs, 43rd Series: Draft Leniency Guidelines and Approval System Guidelines under the Antitrust Law of China
- 2016.03.10
- Recent Developments in Chinese Business Law, No. 43: Draft Guidelines on the Leniency and Approval System under the Anti-monopoly Law of China
- 2015.11.15
- 100 Selected Cases in China, Series 225: A Case Involving the Copyrightable Nature of the Production of Match-up Games in an Online Battle Game
- 2015.08.10
- Latest Updates on Chinese Business Legal Affairs, 36th Series: Ad-hoc Arbitrations and Relevant Practices in China
- 2015.05.13
- Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (2)
- 2015.04.14
- Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (1)
- 2015.02.12
- Is an Agreement Requiring Arbitration In China by a Foreign Arbitration Body Valid?
- 2014.11.20
- 100 Selected Cases in China, 213th Series: A Case Involving the Liability of a Proprietor of an Online Shopping Mall for the Sale of Articles Infringing Trademark Rights
- 2014.11.19
- Latest Updates on Chinese Business Legal Affairs, 29th Series: Current Risks of Non-Compliance in China and Penalties Therefor - GSK China's Commercial Bribery Case where a 53 Billion Yen Fine was Imposed
- 2014.03.10
- Latest Updates on Chinese Business Legal Affairs, 22nd Series: Reformation of the Registered Capital System in China
- 2014.02.10
- Collection of Claims and Information Disclosure by Courts in China
- 2013.08.10
- Latest Updates on Chinese Business Legal Affairs, 15th Series: Latest Updates on the CIETAC Spin Off Issue
- 2013.03.15
- 100 Selected Cases in China, 193rd Series: The Case Dismissing Apple's Claim for Confirmation of the Attribution of Trademark Rights to the iPad
- 2012.11.10
- Latest Updates on Chinese Business Legal Affairs, 8th Series: Promulgation of the Tertiary Guiding Cases Determined by the Supreme People's Court
- 2011.12.15
- 100 Selected Cases in China, 178th Series: The Case where the Judgment Upheld a Claim for Indemnification of Damages and Return of Unjust Enrichment concerning Abuse of Shareholders' Right
- 2011.06.15
- Feature Article: On the Current Enforcement under the Antitrust Law in China - Practical Considerations on Antitrust Law in China
- 2010.12.15
- Current Legal Risks and Considerations concerning Business in China as an Audit & Supervisory Board Member
MORE
Other publications about Cosmetics & Health/Beauty Care Products
MORE
Other publications about Research and Development
MORE
Other publications about Chinese Practice
- 2024.09.26
- [Report from China] How about a CASE like this?
- 2024.09.26
- Legal Affairs for Chinese Life Sciences and Healthcare No. 22: Shanghai Cosmetics Industry Advertising Compliance Guidelines
- 2024.09.26
- New Developments in the Cross-Border Transfer of Data in Free Trade Zones - Consideration of Cross-Border Transfer of Data in the Tianjin Free Trade Zone Data (Negative List) and Cross-Border Transfer of Data in the Shanghai Free Trade Zone (General Data List) with a focus on the Biomedical Sector
- 2024.07.24
- [Report from China] Comparing Sino-Japanese Court Cases
- 2024.07.24
- Brief Analysis of the Provisional Rules for the Prevention of Unfair Network Competition
- 2024.06.26
- [Report from China] Were they all that precise?
- 2024.06.26
- Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 5: Rights of Minority Shareholders under the Chinese Corporation Law
- 2024.05.24
- [Report from China] Japanese Movies and TV Dramas in China
- 2024.05.24
- Restructuring and Withdrawal of Chinese Subsidiaries (6)- Withdrawal (ii) Dissolution, Liquidation and Bankruptcy
- 2024.05.24
- Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 4: Amendment to the Chinese Corporate Law and Liability of Management
- 2024.04.24
- [Report from China] Transition to a Cash-friendly China
- 2024.04.24
- Restructuring and Withdrawal of Chinese Subsidiaries (5)- Withdrawal (i) Share Assingment
- 2024.04.24
- Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 3: Amendments to the Capitalization System of a Company
- 2024.04.10
- Foreign Filling Restrictions of Major Countries －Mechanisms to Restrict Foreign Filing of Sensitive Inventions－
- 2024.03.22
- [Report from China] Has Deflation Begun? Changing Consumption Styles in China
- 2024.03.22
- Restructuring and Withdrawal of Chinese Subsidiaries (4) - Restructuring (iii) Company Split and Business Transfer
- 2024.03.22
- Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 2: Revisions to the Design of Company Organizations
- 2024.02.22
- [Report from China] Knowing China through Tea
- 2024.02.22
- Restructuring and Withdrawal of Chinese Subsidiaries (3) - Restructuring (ii) Administration Services Company
- 2024.01.24
- [Report from China] Miscellaneous Thoughts in My 12th Year of Living in Shanghai
- 2024.01.24
- Restructuring and Withdrawal of Chinese Subsidiaries (2) - Restructuring (i) Merger
- 2024.01.24
- Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
- 2024.01.24
- Chinese Corporate Law in the New Era and Its Impact on Foreign-Invested Enterprises – Part 1: The First Major Revision Since 2005 and an Outline Thereof
- 2023.12.26
- [Report from China] Marathons Familiar to the Chinese People
- 2023.12.26
- Restructuring and Withdrawal of Chinese Subsidiaries (1) - Introduction
- 2023.11.28
- [Report from China] Strategy for Eliminate Scalpers in China
- 2023.11.28
- Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
- 2023.11.28
- Response to the Risk of Misconduct in Business in China (5) - Changes in the Business Environment in China and Efforts to Maintain Business Health
- 2023.11.20
- Inventions Made Across Boarders and the Attachment Foreign Filling Restrictions: Conflicts in the Restrictions and How They Are Handled
- 2023.10.27
- [Report from China] It Depends on the Way of Presenting Statistics
- 2023.10.27
- Publication of the Draft Revisions to the Product Quality Law of China
- 2023.09.29
- [Report from China] Playing Golf in China
- 2023.09.29
- Response to the Risk of Misconduct in Business in China(4) - Effect of Cross-border Data Regulations of China: Handling of Personal Information or the like in Internal Investigations
- 2023.08.28
- [Report from China] Chinese Ventures with Great Commercial Enthusiasm
- 2023.08.28
- Obligation to Establish a Quality and Safety Management System in China
- 2023.08.25
- [Serial Article/Legal Affairs for Companies Expanding Overseas] [No.5] Security and Business: Conflict of Nations and Regulation of Certain Companies
- 2023.07.25
- Legal Affairs for Chinese Life Sciences and Healthcare No.19: Handling and Transborder Transfer of Human Genetic Resources and Information in Chinese Domestic Clinical Trials and Scientific Research
- 2023.07.25
- [Report from China] China’s University Entrance Examination System (Gaokao /National College Entrance Examination)
- 2023.05.24
- [Report from China] Labor Day after the Zero-COVID Policy
- 2023.05.24
- Legal Affairs for Chinese Life Sciences and Healthcare No.18: Enactment of Regulations on Toothpaste in China
- 2023.04.26
- [Report from China] Chat GPT and China
- 2023.04.26
- China Transborder Regulation of Personal Data (1)
- 2023.04.26
- Response to the Risk of Misconduct in Business in China(3) - Establishment of an Internal Control System and Allocation of Management Resources in a Chinese Subsidiary
- 2023.03.28
- [Report from China] Spring is the Season for Politics
- 2023.03.28
- Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
- 2023.03.28
- Response to the Risk of Misconduct in Business in China(2) - Facilitating Information Sharing with Chinese Subsidiaries
- 2023.02.28
- Response to the Risk of Misconduct in Business in China – Focusing on the Response to Signs of Misconduct
- 2023.02.28
- Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
- 2023.02.28
- A Commentary on the New Draft Amendment to the “Companies Law” of China – In Comparison with the First Draft Amendment
- 2023.02.27
- China’s Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
- 2023.01.20
- [Report from China] Traveling to China Immediately after the Lifting of the “Zero-Covid” Policy
- 2023.01.20
- Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
- 2023.01.20
- Labor Issues after Reclassification of the Novel Coronavirus Infectious Disease as a “Category B Infectious Disease Managed under Category B Protocols”
- 2022.12.28
- [Report from China] Reversal of the Policies for the Novel Coronavirus Pandemic
- 2022.12.28
- Labor Issues after Relaxation of the Policies for the Novel Coronavirus Pandemic
- 2022.11.29
- [Report from China] My Experience When China’s Health Code System Indicated a Yellow Code
- 2022.10.25
- [Report from China] The National Congress of the Communist Party of China and the National People’s Congress
- 2022.10.25
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 13) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
- 2022.10.25
- Review of the Draft Amendment to the “Company Act” in China - Revisions to Organizational Structure and the Impact on Japanese Companies -
- 2022.09.27
- [Report from China] National Holidays in China
- 2022.09.27
- Summary of the Amendment to the Chinese Anti-Monopoly Law (2) – Monopoly agreements and abuses of dominant market positions
- 2022.08.22
- Summary of the Amendment to the Chinese Anti-Monopoly Law (1) – Combination of business operators
- 2022.08.22
- [Report from China] Car License Plate Situation in Shanghai
- 2022.07.26
- [Report from China] A Double Whammy with the Inflation and the Weak Yen
- 2022.07.26
- Standard Agreement on the Extraterritorial Transfer of Personal Information
- 2022.07.04
- China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
- 2022.07.04
- Legal Compliance of Workplace Surveillance in China -From a Personal Information Protection Perspective
- 2022.06.23
- [Report from China] Shanghai After the Lifting of the Lockdown
- 2022.05.26
- [Report from China] Shanghai Lockdown to be Fully Lifted by Mid to Late June
- 2022.05.26
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
- 2022.04.27
- [Report from China] Lockdown in Shanghai Continues with No End in Sight
- 2022.04.27
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 9) - [Subsidiary Regulations on Administrative Measures for Monitoring of Adverse Reactions to Cosmetics] Overview
- 2022.04.27
- Addressing Legal Issues Relating to the Resurgence of Covid-19 in China - Focusing on Treatment of Employees and Actions toward Trading Counterparties
- 2022.03.24
- [Report from China] Latest on the Novel Coronavirus in China - Will the Government Change its Zero-Covid Policy?
- 2022.03.24
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
- 2022.03.24
- Addressing the Bankruptcy or Liquidation Risk of Chinese Trading Counterparties - Key Points of Claim Collection Bearing in Mind the Risk of Corporate Bankruptcy
- 2022.03.14
- A Legal Review of China’s Life Sciences and 2 Healthcare- No.1 －General Introduction and MAH System
- 2022.03.14
- A Few Key Points of the China Personal Information Protection Law
- 2022.02.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
- 2022.02.21
- [Report from China] Chinese New Year and Beijing Winter Olympic Games
- 2022.02.21
- System and Legislative Framework Relating to Carbon Emission Trading in China
- 2022.01.21
- [Report from China] Ten Years in Shanghai Saw Many Changes
- 2022.01.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
- 2022.01.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
- 2022.01.21
- China’s Anti-foreign Sanctions Law and Points that Foreign Corporations should Note
- 2021.12.22
- Personal Information Protection Law of China (2) – Processing of Personal Information and Consent by the Data Subject -
- 2021.12.22
- [Report from China] Digital Yuan and Electronic Payment
- 2021.11.24
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) –
Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
- 2021.11.24
- Measures on Security Assessment of Cross-Border Data Transfers (Draft for Comment) - Basic Points to Note -
- 2021.10.28
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) –
Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
- 2021.10.28
- Personal Information Protection Law of China (1) - Basic Points to Note -
- 2021.09.30
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
- 2021.09.30
- Looking Back on the First 4 Years of the “Network Security Law” in China (Part II) -China's Regulations on Cross-border Transfer of Data, Etc.
- 2021.08.30
- Looking Back on the First 4 Years of the “Network Security Law” (Part I)
- 2021.08.30
- Legal Affairs for Chinese Life Sciences and Healthcare
- 2019.10.15
- Points to Consider Regarding Advertising Expressions when Doing Business in China
- 2019.05.10
- Case Study on Court Judgement in China Regarding Recognition and Enforcement of Foreign or External Arbitral Award
- 2019.03.22
- Building a Compliance System for China-based Affiliates – Mainly on the Aspects of Transactions
- 2018.12.10
- Acts against Unjustifiable Advertisement and Misleading Representations in China
- 2018.04.24
- Case Study on Court Judgment in China Regarding Recognition and Enforcement of Foreign Arbitral Award (14)
- 2017.12.27
- 100 Selected Cases in China, Series 250
- 2017.02.01
- Chinese Business Law System
- 2017.02.01
- Chinese Business Law System: Organized by Internal Division and by Situation [Second Edition]
- 2016.12.01
- Property Preservation in China - Provisions of the Supreme People's Court on several issues concerning the handling of property preservation cases by the people's court
- 2016.02.10
- [Theory and Practice on Civil and Commercial Law in China (97)] Structure of Cross-Border E-Commerce with China and Legal Points to Note therein
- 2015.09.05
- [Special Report] Risks Involved in Overseas Business Expansions of Small and Medium-Sized Enterprises, and Countermeasures Therefor _ Focusing on Legal Risks in China, Thailand, Vietnam and Indonesia -
- 2015.02.01
- Supreme People's Court decision on Abuse of Market Dominant Position under China’s Antitrust Law
- 2014.10.01
- Regulations and Countermeasures in Respect of Chinese Monopoly Agreements -12 Japanese Auto Parts Suppliers are fined 20 Billion Yen
- 2014.06.01
- 100 Selected Cases in China (No. 208): An Introduction and Brief Study on the Notice of the Supreme People's Court of PRC on Publishing the Sixth Batch of Guiding Precedents.
- 2014.06.01
- "(4) Part 1: Basic Legal System of lawsuits concerning Intellectual Property Rights in China" (co-authored)
- 2014.03.01
- “Textbook on Chinese Legal Practice - From Entry to Withdrawal”
- 2013.06.01
- Antitrust in the Emerging Economies of Asia: China and Indonesia
- 2013.05.01
- Recent Amendments and Judicial Interpretation of Labor Related Regulations in China: Focusing on Amendments to the Labor Contract Law in China
- 2013.01.01
- Outline and Practical Issues of Title Retention in Sales Contracts in China
- 2012.06.01
- 100 Selected Cases in China (No. 184): Case where the act of the managing company of a video-sharing site in providing data storage space to users who upload movies to such site was held to qualify as aiding copyright infringement
- 2011.10.01
- China "Interim Provisions on Assessing the Impact of the Concentration of Business Operators on Competition"
- 2011.09.01
- China "Interim Provisions on Assessing the Impact of the Concentration of Business Operators on Competition" (Draft for Public Comments)
- 2010.11.01
- “The Roles that Banks Can Play in their Clients' Expansion in China”
- 2009.04.01
- Global Intellectual Property Strategies for Companies Doing Business in China
- 2009.04.01
- Withdrawal by Transfer of Equity Interest
- 2006.11.01
- The Introduction of the Draft Antitrust Law of China and the Risk for Foreign Enterprises
- 2006.04.01
- Guide to International Legal Practice (1) to (11)
MORE
Other publications about Marketing Regulation
- 2024.01.24
- Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
- 2023.11.28
- Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
- 2023.08.24
- Thematic-based: Legal Practice in the Healthcare Business
- 2022.07.04
- China’s Life Sciences and Healthcare-No.2 －The Good Vigilance Practice rule in China
- 2022.05.26
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
- 2022.03.24
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
- 2022.02.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (2)
- 2022.01.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
- 2022.01.21
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 6) - Trial Program for Cross-border E-commerce Retail Import of Drugs in Henan
- 2021.11.24
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) –
Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
- 2021.10.28
- Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) –
Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
MORE
Contact us
